US20030029725A1 - Separation of micromolecules - Google Patents

Separation of micromolecules Download PDF

Info

Publication number
US20030029725A1
US20030029725A1 US10/265,798 US26579802A US2003029725A1 US 20030029725 A1 US20030029725 A1 US 20030029725A1 US 26579802 A US26579802 A US 26579802A US 2003029725 A1 US2003029725 A1 US 2003029725A1
Authority
US
United States
Prior art keywords
membrane
separation
chamber
molecular mass
restriction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/265,798
Inventor
Brendon Conlan
Andrew Gilbert
Lucy Ryan
Chenicheri Nair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/265,798 priority Critical patent/US20030029725A1/en
Publication of US20030029725A1 publication Critical patent/US20030029725A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D57/00Separation, other than separation of solids, not fully covered by a single other group or subclass, e.g. B03C
    • B01D57/02Separation, other than separation of solids, not fully covered by a single other group or subclass, e.g. B03C by electrophoresis

Definitions

  • the present invention relates to apparatus and methods for the separation of molecules, particularly micromolecules having a molecular mass of less than about 5000 Dalton.
  • micromolecules there are increasing numbers of micromolecules being used as food and diet supplements, pharmaceuticals and neutraceuticals. Increasing numbers of vitamins, co-factors, plant and microbial extracts are also being developed and used for human and animal consumption. As many of these compounds are micromolecules,(having a molecular mass of less than about 5000 Dalton (Da)), there is a need to develop methods to separate or purify these compounds in a fast and economical manner. Traditional separation methods for micromolecules can alter or denature these compounds. Separation methods for larger molecules typically are not considered suitable for use in micromolecule separation. Furthermore, traditional methods can be quite time consuming, expensive and difficult to scale up commercially.
  • the subject invention overcomes the above limitations and others, and teaches an electrophoresis system, which can be scaled up for preparative applications, which apparatus can efficiently and effectively separate micromolecules.
  • an apparatus for separating micromolecules by electrophoretic separation comprising:
  • (f) means adapted to provide a sample constituent in a selected one of the first and second interstitial volumes
  • a selected separation product is removed from the sample constituent, thorough the separation membrane, and provided to the other of the first and second interstitial volume and wherein a micromolecule is capable of being retained in at least one of the interstitial volumes.
  • an apparatus for separating micromolecules by electrophoresis comprising:
  • the buffer compartments, the first chamber and the second chamber are configured to allow flow of the respective buffer, first and second solutions forming streams.
  • large volumes can be processed quickly and efficiently.
  • the solutions are typically moved or recirculated through the compartments and chambers from respective reservoirs by pumping means.
  • Peristaltic pumps have been found to be particularly suitable for moving the fluids.
  • the ion-permeable separation membrane has a molecular mass cut-off greater than the molecular mass of the micromolecule to be separated.
  • An advantage of the present invention is that micromolecules can be separated efficiently and effectively using preparative electrophoresis under near native conditions which results in higher yields and excellent recovery.
  • Another advantage of the present invention is that the system is suitably used in a number of other areas, especially in the production of biological components for medical use.
  • Another advantage of the present invention is that the system can be suitably configured to remove biological contaminants at the point of separation.
  • FIG. 1 shows the transfer of BB-FCF through the 5 kDa separation membrane from the sample stream (US) where it transiently builds up in the product stream (DS). After 20 minutes all the BB-FCF had transferred through the bottom restriction membrane into the buffer stream where it was lost.
  • FIG. 2 shows Azorubine transfer using only polyacrylamide membranes in the Gradiflow system. Transfer from the sample (US) to the product stream (DS) occurred but the molecules only built up for a small period of time before moving completely into the buffer stream.
  • FIG. 3 shows that Biotin behaves in a similar manner to the other tested micromolecules in that it transferred rapidly from the sample stream (US) and appeared transiently in the product stream (DS) before eluting into the buffer stream.
  • FIG. 4 shoes that phytoestrogen transferred into the product stream (DS) from the sample stream (US), where it built up and over time before dissipating into the buffer stream.
  • FIG. 5 shows BB-FCF separated with 74% yield in one hour.
  • the molecules were readily captured using the 1 kDa ultrafiltration membrane in the cartridge.
  • FIG. 6 shows the level of Azorubine in the sample stream (US) decreased over time and transferred to the product stream (DS). A total of 83% of the Azorubine was transferred and retained in 45 minutes.
  • FIG. 7 shows Biotin was readily transferred from the sample stream into the product stream and collected with high yield (84%) in the product stream.
  • FIG. 8 shows phytoestrogen was transferred from the sample stream into the product stream where it could be collected.
  • FIG. 9 shows separation of BB-FCF from Azorubine in a system adapted to carry out the method according to the present invention.
  • the BB-FCF was retained in the sample stream whilst the Azorubine was moved to the product stream.
  • FIG. 10 shows BB-FCF was separated from Azorubine using a size exclusion approach with retention of 74% of the BB-FCF. Only a small percentage of the Azorubine remained with the BB-FCF after three hours of separation.
  • FIG. 11 is a schematic view of a preferred embodiment of the separation apparatus of the present invention.
  • This invention is directed to an apparatus and method for the separation of molecules, particularly micromolecules having a molecular mass of less than about 5000 Dalton.
  • the present invention is directed to an apparatus for separating micromolecules by electrophoretic separation, the apparatus comprising:
  • (f) means adapted to provide a sample constituent in a selected one of the first and second interstitial volumes
  • a selected separation product is removed from the sample constituent, thorough the separation membrane, and provided to the other of the first and second interstitial volumes, and wherein a micromolecule is capable of being retained in at least one of the interstitial volumes.
  • the present invention is directed an apparatus for separating micromolecules by electrophoresis, the apparatus comprising:
  • the buffer compartments, the first chamber and the second chamber are configured to allow flow of the respective buffer, first and second solutions forming streams.
  • large volumes can be processed quickly and efficiently.
  • the solutions are typically moved or recirculated through the compartments and chambers from respective reservoirs by pumping means.
  • Peristaltic pumps have been found to be particularly suitable for moving the fluids.
  • the ion-permeable separation membrane has a molecular mass cut-off greater than the molecular mass of the micromolecule to be separated.
  • FIG. 11 shows a preferred embodiment of the apparatus 10 of the present invention.
  • the apparatus 10 includes an anode buffer zone or compartment 11 and a cathode buffer zone or compartment 12 separated by an ion-permeable separation barrier 13 .
  • Electrodes 14 and 15 are provided inside the buffer zones or compartments so as to be on opposite sides of the separation membrane 13 . It is understood, however, that in another embodiment, the electrodes are positioned outside the buffer compartments. The electrodes are used to apply an electrophoretic potential across the separation membrane.
  • a first chamber 16 is positioned between the anode buffer compartment 11 and the separation membrane 13 .
  • the first chamber is defined on one side by the separation membrane 13 and on the other side by a first restriction membrane 18 . It is understood, however, that in another embodiment, the first chamber is positioned between the cathode buffer compartment and the separation membrane.
  • the first restriction membrane is comprised of at least two membranes 18 and 18 b having distinctive pore sizes.
  • a second chamber 17 is positioned between the cathode buffer compartment 12 and the separation barrier 13 .
  • the second chamber is defined on one side by the separation membrane 13 and on the other side by a second restriction membrane 19 on the other side. It is understood, however, that in another embodiment, the second chamber is positioned between the anode buffer compartment and the separation membrane.
  • the second restriction membrane is comprised of at least two membranes 19 a and 19 b having distinctive pore sizes.
  • the apparatus is further comprised of switch 25 for selection of the application of a voltage source (such as to turn the voltage source off or have resting periods), switch 26 to switch current direction for cathode/anode or to have reversal periods, and voltage sources 27 and 28 .
  • a voltage source such as to turn the voltage source off or have resting periods
  • switch 26 to switch current direction for cathode/anode or to have reversal periods
  • voltage sources 27 and 28 are further comprised of switch 25 for selection of the application of a voltage source (such as to turn the voltage source off or have resting periods)
  • the anode buffer compartment and the cathode buffer compartment are supplied with suitable buffer solutions by any suitable means.
  • a mixture comprising micromolecules is supplied directly to the first chamber by any suitable means.
  • the micromolecules are separated from the second chamber by any suitable means.
  • the buffer compartments, the first chamber and the second chamber are configured to allow flow of the respective buffer, sample and product solutions forming streams.
  • large volumes can be processed quickly and efficiently.
  • the solutions are typically moved or recirculated through the compartments and chambers from respective reservoirs by pumping means.
  • peristaltic pumps are used as the pumping means for moving the fluids.
  • the buffer, sample or product solutions are cooled by any suitable means to ensure no inactivation of the micromolecules occurs during the separation process and to maintained a desired temperature of the apparatus while in use.
  • solution in the product chamber or stream is collected and replaced with suitable solvent to ensure that electrophoresis can continue.
  • At least one restriction membrane is formed as a composite or sandwich arrangement with at least two materials.
  • at least one restriction membrane is formed as a sandwich arrangement with at least two layers of material.
  • the sandwich arrangement includes an inner layer (facing the separation membrane in the first and second solvent streams, respectively) comprising a membrane having a pore size with a molecular mass cut-off less than the about 5000 Da and an outer layer comprising a membrane having a molecular mass cut-off of greater than about 5000 Da.
  • the inner layer is made from an ultrafiltration, electrodialysis or haemodialysis material and the outer layer is made from polyacrylamide.
  • the outer layer provides some structural support for the filtration membrane while preventing unwanted movement of fluid.
  • the pore size of the filtration membrane is selected according to the size of the micromolecule to be separated such that the micromolecule cannot pass through the membrane.
  • the molecular mass cut-off of the filtration membrane is between about 100 Da to 5000 Da. More preferably, the molecular mass cut-off is around 200 Da.
  • Hydrogel ion-permeable separation membranes an ultrafiltration, electrodialysis and/or haemodialysis membranes coated with polyacrylamide
  • Such membranes are possible to manufacture, but are currently not commercially available.
  • the ion-permeable separation barrier is a membrane made from polyacrylamide and having a molecular mass cut-off from about 5 to 1000 kDa.
  • the size of the separation membrane cut-off will depend on the sample being processed and the other molecules in the mixture.
  • restriction barriers or membranes positioned adjacent the sample and product chambers can have the same molecular mass cut-off or different cut-offs therefore forming an asymmetrical arrangement.
  • the restriction membrane separating the product chamber from the buffer compartment is formed in a sandwich configuration.
  • the distance between the electrodes can have an effect on the separation or movement of micromolecules through the barriers. It has been found that the shorter the distance between the electrodes, the faster the electrophoretic movement of micromolecules. A distance of about 6 cm has been found to be suitable for a laboratory scale apparatus. For scale up versions, the distance will depend on the number and type of separation membranes, the size and volume of the chambers for samples, buffers and separated products. Preferred distances would be in the order of 6 cm to about 10 cm. The distance will also relate to the voltage applied to the apparatus. The effect of the electric field is based on the equation:
  • the distance between the electrodes should decrease in order to increase electric field strength, thereby further improving transfer rates.
  • Flow rate of sample/buffer can have an influence on the separation of micromolecules. Rates of milliliters per hour up to liters per hour can be used depending on the configuration of the apparatus and the sample to be separated. Currently in a laboratory scale instrument, the preferred flow rate is about 20 ⁇ 5 mL/min. However, flow rates ranging from about 0 to about 50,000 mL/min are also used across the various separation regimes. In some embodiments the maximum flow rate is higher, depending on the pumping means and size of the apparatus. The flow rate is dependent on the product to be transferred, efficiency of transfer, pre- and post-positioning with other applications.
  • Voltage and/or current applied can vary depending on the separation. Typically up to several thousand volts may be used but choice and variation of voltage will depend on the configuration of the apparatus, buffers and the sample to be separated. In a laboratory scale instrument, the preferred voltage is about 250 V. However, depending on transfer, efficiency, scale-up and particular method about 0 to about 5000 are used. Higher voltages may also be considered, depending on the apparatus and sample to be treated.
  • a number of first and second chambers could be stacked in the one apparatus for use in a scale-up device.
  • a single stream configuration can be produced where the second chamber forms a buffer chamber. In this configuration, contaminants would be moved out of the first chamber into the buffer compartments and the product of interest retained in the first chamber.
  • the membranes can have either a symmetric or asymmetric arrangements. The present invention also includes these embodiments.
  • a sample containing one or more micromolecules is added to the first chamber and an electric potential is applied to cause movement of at least one micromolecule from the sample through the separation membrane into the second chamber while the restriction membranes prevent movement of micromolecules from the first or the second chambers into the respective electrophoresis buffer chambers.
  • the micromolecule is removed and collected from the product chamber.
  • the present invention provides a separation cartridge suitable for use in an electrophoresis apparatus for separating micromolecules, the cartridge comprising:
  • the cartridge further includes:
  • the separation barrier is a membrane composed of polyacrylamide and having a molecular mass cut-off from about 5 to 1000 kDa.
  • the ion-permeable separation membrane has a molecular mass cut-off greater than the molecular mass of the micromolecule to be separated.
  • At least one restriction membrane is preferably formed as a sandwich or composite arrangement of membranes with at least two materials.
  • the sandwich arrangement includes an inner layer comprising a restriction membrane having a pore size with a molecular mass cut-off less than about 5000 Da and an outer layer comprising a restriction membrane having a molecular mass cut-off of greater than about 5000 Da.
  • the inner layer is made from an ultrafiltration, electrodialysis or haemodialysis material and the outer layer is made from polyacrylamide.
  • the outer layer provides some structural support for the filtration membrane while preventing unwanted movement of fluid.
  • the pore size of the filtration membrane is selected according to the size of the micromolecule to be separated such that the micromolecule cannot pass through the membrane.
  • the molecular mass cut-off of the filtration membrane is between about 100 Da to 5000 Da. More preferably, the molecular mass cut-off is around 200 Da.
  • the present invention provides a method of separating a micromolecule from a liquid sample, the method comprising:
  • the micromolecule can be any micromolecule capable of receiving or having a charge. Examples include, but not limited to, biotin, Brilliant Blue FCF (BB FCF), azorubine, phytoestrogen, digoxigenin, hormones, cytokines, dyes, vitamins, chemicals, neutraceuticals, pharmaceuticals along with food and diet supplements.
  • BB FCF Brilliant Blue FCF
  • azorubine phytoestrogen
  • digoxigenin digoxigenin
  • hormones cytokines
  • dyes vitamins, chemicals, neutraceuticals, pharmaceuticals along with food and diet supplements.
  • the sample can contain one or more micromolecules of interest.
  • micromolecules of interest examples include, but are not limited to, crude extracts, microbial cultures, cell lysates, cellular products, chemical processing mixtures, cell culture media, plant products or extracts.
  • Solvent in the form of buffers that have been found to be particularly suitable for the method according to the present invention are Tris Borate around pH 9. It will be appreciated, however, that other buffers or solvents would also be suitable, depending on the separation.
  • the concentration of the selected buffers can also influence or effect the movement of micromolecules through the separation barrier. Typically concentrations of about 10 mM to about 200 mM, more preferably 20 mM to 80 mM, have been found to be particularly suitable. Almost any buffers and/or solvents can be used with the present invention.
  • the buffers and/or solvents that can be used are procedure/method/separation dependent. The concentration of the buffer and/or solvent is dependent upon the application/separation/procedure.
  • Reversal of current is an option but another embodiment is a resting period. Resting (a period without an electric potential being applied, but pumps remain on) is an optional step that can replace or be included before or after an optional electrical potential reversal. This reversal technique is often practised for protein separation work as an alternative to reversing the potential.
  • One benefit of the method according to the present invention is the possibility of scale-up without denaturing or adversely altering the physical or biological properties of the micromolecule.
  • the present invention provides a micromolecule purified or separated by the method according to the third aspect of the present invention.
  • the micromolecule is less than 5000 Da.
  • examples include, but are not limited to, biotin, Brilliant Blue FCF (BB FCF), azorubine, phytoestrogen, digoxigenin, hormones, cytokines, dyes, vitamins, chemicals, neutraceuticals, pharmaceuticals along with food diet supplements, and combinations thereof.
  • the present invention relates to use of the micromolecule according to the fourth aspect of the present invention in dietary, medical and veterinary applications.
  • hydrogel polyacrylamide membranes traditionally used in the earlier system's cartridge were placed as backing to a commercial membrane with the desired pore size.
  • the polyacrylamide membrane is useful to prevent unregulated fluid movement across the membranes, whilst the commercial membrane is used to retain the smaller molecular species within the sample or product streams or chambers.
  • the membranes used for this work were Pall Gelman Omega ultrafiltration membranes. These ultrafiltration membranes are available commercially with pore sizes ranging from hundreds of kDa down to 1000 Da.
  • Vitamin H Vitamin H
  • the other a small phytoestrogen separated from red leaf clover (supplied by Novogen, Sydney Australia).
  • Brilliant Blue FCF and Azorubine are two chemicals currently used in the food industry as colouring agents.
  • Biotin has several uses, first as a necessary vitamin in the human diet and secondly, but not insignificantly, as a labelling agent in scientific assays.
  • Phytoestrogens are separated commercially from many sources primarily soy and clover where they are made into herbal and pharmaceutical medicines.
  • FIGS. 1, 2, 3 , and 4 show the transient build up and eventual loss of BB-FCF, Azorubine, Biotin, and the Phytoestrogen, within the an apparatus used for macromolecule separation having only polyacrylamide membranes.
  • the time taken for the micromolecules to completely transfer out of the system varies for each molecule. It is likely that this is due to the difference in charge to mass ratios between the molecules.
  • Azorubine was moved across the separation membrane and collected in the product stream. Using a pH 9.0 Tris-Borate buffer 83% of the Azorubine was transferred from the sample stream to the product stream within 45 minutes. This transfer was measured using the absorbance of Azorubine at 516 nm. The separation is illustrated in FIG. 4.
  • the Biotin separation utilised a pH 9.0 buffer with the same cartridge configuration as that used for the BB-FCF and Azorubine. The transfer of this molecule was monitored using the absorbance at 230 nm. This experiment showed that the 1 kDa ultrafiltration membrane used could retain molecules as small as 244 Dalton.
  • FIG. 7 shows that over 80% of the Biotin was transferred to the product stream where it was contained.
  • the phytoestrogen transfer experiment depicted in FIG. 8 showed the movement and successful capture of phytoestrogen. The decrease over time after the initial high levels of phytoestrogen are most likely due to the fact that a 5 kDa ultrafiltration membrane was used as the bottom restriction membrane. The use of a 1 kDa ultrafiltration membrane would help to completely retain the small phytoestrogen.
  • BB-FCF was separated from Azorubine.
  • the concentration of Azorubine decreased significantly from the sample stream but did not build up substantially in the product stream. This was due to loss into the buffer stream over time.
  • the BB-FCF can pass through a 3 kDa membrane but only very slowly so separation of the two molecules was achieved. The movement of both molecules was monitored using 603 nm for BB-FCF and 516 nm for Azorubine.
  • FIG. 9 shows the selective nature of the separation.

Abstract

This invention is directed to an apparatus and method for the separation of molecules, particularly micromolecules having a molecular mass of less than 5000 Dalton. The present invention is directed to an apparatus for separating micromolecules by electrophoretic separation, the apparatus comprising:
(a) an anode;
(b) a cathode disposed relative to the anode so as to be adapted to generate an electric field in an electric field area therebetween upon application of a voltage potential between the anode and the cathode;
(c) a separation membrane disposed in the electric field area;
(d) a first restriction membrane disposed between the anode and the separation membrane so as to define a first interstitial volume therebetween;
(e) a second restriction membrane disposed between the cathode and the separation membrane so as to define a second interstitial volume therebetween; and
(f) means adapted to provide a sample constituent in a selected one of the first and second interstitial volumes;
wherein upon application of the voltage potential, a selected separation product is removed from the sample constituent, thorough the separation membrane, and provided to the other of the first and second interstitial volumes, wherein a micromolecule is capable of being retained in at least one of the interstitial volumes, and wherein a micromolecule is capable of being retained in at least one of the interstitial volumes.

Description

    BACKGROUND OF THE INVENTION
  • The present invention relates to apparatus and methods for the separation of molecules, particularly micromolecules having a molecular mass of less than about 5000 Dalton. [0001]
  • There are increasing numbers of micromolecules being used as food and diet supplements, pharmaceuticals and neutraceuticals. Increasing numbers of vitamins, co-factors, plant and microbial extracts are also being developed and used for human and animal consumption. As many of these compounds are micromolecules,(having a molecular mass of less than about 5000 Dalton (Da)), there is a need to develop methods to separate or purify these compounds in a fast and economical manner. Traditional separation methods for micromolecules can alter or denature these compounds. Separation methods for larger molecules typically are not considered suitable for use in micromolecule separation. Furthermore, traditional methods can be quite time consuming, expensive and difficult to scale up commercially. [0002]
  • In the past, a preparative electrophoresis technology for macromolecule separation which utilises tangential flow across a polyacrylamide membrane when a charge is applied across the membrane was used to separate micromolecules. The general design of the earlier system facilitated the purification of proteins and other macromolecules under near native conditions. The technology is bundled into a cartridge comprising several membranes housed in a system of specially engineered grids and gaskets which allow separation of macromolecules by charge and/or molecular weight. The system can also concentrate and desalt/dialyse at the same time. The multi-modal nature of the system allows this technology to be used in a number of other areas especially in the production of biological components for medical use. The technology isolates macromolecules using the duality of charge and size. However, the technology could not be extended to the isolation of molecules below about 5000 Da. This meant that while molecules smaller than 5000 Da could be removed using at least charge-based separation, the resulting target molecule could not be captured. [0003]
  • The separation of micromolecules, molecules deemed to be less than about 5 kDa, was previously thought not to be possible using electrophoresis technology devised to separate macromolecules. This was due to the limit in pore size of membranes normally used in the systems. For example, the smallest cut-off produced in polyaccrylamide membranes is about 5 kDa which will retain any molecule larger than 5 kDa. [0004]
  • There were several problems encountered in the separation of micromolecules using an unmodified electrophoresis system. Difficulty retaining micromolecules in the system has been overcome with the addition of combinations of membranes. However, these membranes themselves posed problems in that they are not designed to retain liquids and can produce large levels of electro-endo-osmosis. The liquid retention problem has been solved by backing the membranes with the hydrogel polyacrylamide membranes, which also helped to reduce the electro-endo-osmosis levels. [0005]
  • It is desirable to have a preparative electrophoresis system which can efficiently and effectively remove micromolecules. [0006]
  • The subject invention overcomes the above limitations and others, and teaches an electrophoresis system, which can be scaled up for preparative applications, which apparatus can efficiently and effectively separate micromolecules. [0007]
  • SUMMARY OF THE INVENTION
  • In accordance with the present invention, there is provided an electrophoresis system which efficiently and effectively separate micromolecules. [0008]
  • Further, in accordance with the present invention, there is provided an apparatus for separating micromolecules by electrophoretic separation, the apparatus comprising: [0009]
  • (a) an anode; [0010]
  • (b) a cathode disposed relative to the anode so as to be adapted to generate an electric field in an electric field area therebetween upon application of a voltage potential between the anode and the cathode; [0011]
  • (c) a separation membrane disposed in the electric field area; [0012]
  • (d) a first restriction membrane disposed between the anode and the separation membrane so as to define a first interstitial volume therebetween; [0013]
  • (e) a second restriction membrane disposed between the cathode and the separation membrane so as to define a second interstitial volume therebetween; and [0014]
  • (f) means adapted to provide a sample constituent in a selected one of the first and second interstitial volumes; [0015]
  • wherein upon application of the voltage potential, a selected separation product is removed from the sample constituent, thorough the separation membrane, and provided to the other of the first and second interstitial volume and wherein a micromolecule is capable of being retained in at least one of the interstitial volumes. [0016]
  • Still further, in accordance with the present invention, there is provided an apparatus for separating micromolecules by electrophoresis, the apparatus comprising: [0017]
  • (a) an anode buffer compartment and a cathode buffer compartment; [0018]
  • (b) electrodes positioned in the buffer compartments; [0019]
  • (c) a first chamber and a second chamber positioned on either side of an ion-permeable separation membrane having a defined molecular mass cut-off, the first chamber and the second chamber being positioned between the anode and the cathode buffer compartments and separated by an ion-permeable restriction membrane positioned on each side of the separation membrane, the restriction membrane(s) allowing flow of ions into and out of the compartments and chambers under the influence of an electric field but substantially restrict movement of at least one micromolecule type from the second chamber into the buffer compartment. [0020]
  • Preferably, the buffer compartments, the first chamber and the second chamber are configured to allow flow of the respective buffer, first and second solutions forming streams. In this form, large volumes can be processed quickly and efficiently. The solutions are typically moved or recirculated through the compartments and chambers from respective reservoirs by pumping means. Peristaltic pumps have been found to be particularly suitable for moving the fluids. [0021]
  • Preferably, the ion-permeable separation membrane has a molecular mass cut-off greater than the molecular mass of the micromolecule to be separated. [0022]
  • An advantage of the present invention is that micromolecules can be separated efficiently and effectively using preparative electrophoresis under near native conditions which results in higher yields and excellent recovery. [0023]
  • Another advantage of the present invention is that the system is suitably used in a number of other areas, especially in the production of biological components for medical use. [0024]
  • Another advantage of the present invention is that the system can be suitably configured to remove biological contaminants at the point of separation. [0025]
  • These and other advantages and benefits of the invention will be apparent to those skilled in the art upon reading and understanding of the following detailed description.[0026]
  • BRIEF DESCRIPTION OF DRAWINGS [0027]
  • FIG. 1 shows the transfer of BB-FCF through the 5 kDa separation membrane from the sample stream (US) where it transiently builds up in the product stream (DS). After 20 minutes all the BB-FCF had transferred through the bottom restriction membrane into the buffer stream where it was lost. [0028]
  • FIG. 2 shows Azorubine transfer using only polyacrylamide membranes in the Gradiflow system. Transfer from the sample (US) to the product stream (DS) occurred but the molecules only built up for a small period of time before moving completely into the buffer stream. [0029]
  • FIG. 3 shows that Biotin behaves in a similar manner to the other tested micromolecules in that it transferred rapidly from the sample stream (US) and appeared transiently in the product stream (DS) before eluting into the buffer stream. [0030]
  • FIG. 4 shoes that phytoestrogen transferred into the product stream (DS) from the sample stream (US), where it built up and over time before dissipating into the buffer stream. [0031]
  • FIG. 5 shows BB-FCF separated with 74% yield in one hour. The molecules were readily captured using the 1 kDa ultrafiltration membrane in the cartridge. [0032]
  • FIG. 6 shows the level of Azorubine in the sample stream (US) decreased over time and transferred to the product stream (DS). A total of 83% of the Azorubine was transferred and retained in 45 minutes. [0033]
  • FIG. 7 shows Biotin was readily transferred from the sample stream into the product stream and collected with high yield (84%) in the product stream. [0034]
  • FIG. 8 shows phytoestrogen was transferred from the sample stream into the product stream where it could be collected. [0035]
  • FIG. 9 shows separation of BB-FCF from Azorubine in a system adapted to carry out the method according to the present invention. The BB-FCF was retained in the sample stream whilst the Azorubine was moved to the product stream. [0036]
  • FIG. 10 shows BB-FCF was separated from Azorubine using a size exclusion approach with retention of 74% of the BB-FCF. Only a small percentage of the Azorubine remained with the BB-FCF after three hours of separation. [0037]
  • FIG. 11 is a schematic view of a preferred embodiment of the separation apparatus of the present invention.[0038]
  • DETAILED DESCRIPTION OF THE INVENTION
  • This invention is directed to an apparatus and method for the separation of molecules, particularly micromolecules having a molecular mass of less than about 5000 Dalton. The present invention is directed to an apparatus for separating micromolecules by electrophoretic separation, the apparatus comprising: [0039]
  • (a) an anode; [0040]
  • (b) a cathode disposed relative to the anode so as to be adapted to generate an electric field in an electric field area therebetween upon application of a voltage potential between the anode and the cathode; [0041]
  • (c) a separation membrane disposed in the electric field area; [0042]
  • (d) a first restriction membrane disposed between the anode and the separation membrane so as to define a first interstitial volume therebetween; [0043]
  • (e) a second restriction membrane disposed between the cathode and the separation membrane so as to define a second interstitial volume therebetween; and [0044]
  • (f) means adapted to provide a sample constituent in a selected one of the first and second interstitial volumes; [0045]
  • wherein upon application of the voltage potential, a selected separation product is removed from the sample constituent, thorough the separation membrane, and provided to the other of the first and second interstitial volumes, and wherein a micromolecule is capable of being retained in at least one of the interstitial volumes. [0046]
  • In a preferred embodiment, the present invention is directed an apparatus for separating micromolecules by electrophoresis, the apparatus comprising: [0047]
  • (a) an anode buffer compartment and a cathode buffer compartment; [0048]
  • (b) electrodes positioned in the buffer compartments; [0049]
  • (c) a first chamber and a second chamber positioned on either side of an ion-permeable separation membrane having a defined molecular mass cut-off, the first chamber and the second chamber being positioned between the anode and the cathode buffer compartments and separated by an ion-permeable restriction membrane positioned on each side of the separation membrane, the restriction membrane(s) allowing flow of ions into and out of the compartments and chambers under the influence of an electric field but substantially restrict movement of at least one micromolecule type from the second chamber into the buffer compartment. [0050]
  • Preferably, the buffer compartments, the first chamber and the second chamber are configured to allow flow of the respective buffer, first and second solutions forming streams. In this form, large volumes can be processed quickly and efficiently. The solutions are typically moved or recirculated through the compartments and chambers from respective reservoirs by pumping means. Peristaltic pumps have been found to be particularly suitable for moving the fluids. [0051]
  • Preferably, the ion-permeable separation membrane has a molecular mass cut-off greater than the molecular mass of the micromolecule to be separated. [0052]
  • FIG. 11 shows a preferred embodiment of the [0053] apparatus 10 of the present invention. The apparatus 10 includes an anode buffer zone or compartment 11 and a cathode buffer zone or compartment 12 separated by an ion-permeable separation barrier 13. Electrodes 14 and 15 are provided inside the buffer zones or compartments so as to be on opposite sides of the separation membrane 13. It is understood, however, that in another embodiment, the electrodes are positioned outside the buffer compartments. The electrodes are used to apply an electrophoretic potential across the separation membrane.
  • A [0054] first chamber 16 is positioned between the anode buffer compartment 11 and the separation membrane 13. The first chamber is defined on one side by the separation membrane 13 and on the other side by a first restriction membrane 18. It is understood, however, that in another embodiment, the first chamber is positioned between the cathode buffer compartment and the separation membrane. In one embodiment, the first restriction membrane is comprised of at least two membranes 18 and 18 b having distinctive pore sizes.
  • A [0055] second chamber 17 is positioned between the cathode buffer compartment 12 and the separation barrier 13. The second chamber is defined on one side by the separation membrane 13 and on the other side by a second restriction membrane 19 on the other side. It is understood, however, that in another embodiment, the second chamber is positioned between the anode buffer compartment and the separation membrane. In one embodiment, the second restriction membrane is comprised of at least two membranes 19 a and 19 b having distinctive pore sizes.
  • The apparatus is further comprised of [0056] switch 25 for selection of the application of a voltage source (such as to turn the voltage source off or have resting periods), switch 26 to switch current direction for cathode/anode or to have reversal periods, and voltage sources 27 and 28.
  • The anode buffer compartment and the cathode buffer compartment are supplied with suitable buffer solutions by any suitable means. A mixture comprising micromolecules is supplied directly to the first chamber by any suitable means. The micromolecules are separated from the second chamber by any suitable means. [0057]
  • Preferably, the buffer compartments, the first chamber and the second chamber are configured to allow flow of the respective buffer, sample and product solutions forming streams. In this form, large volumes can be processed quickly and efficiently. The solutions are typically moved or recirculated through the compartments and chambers from respective reservoirs by pumping means. In a preferred embodiment, peristaltic pumps are used as the pumping means for moving the fluids. [0058]
  • The buffer, sample or product solutions are cooled by any suitable means to ensure no inactivation of the micromolecules occurs during the separation process and to maintained a desired temperature of the apparatus while in use. [0059]
  • Preferably, in order to collect and concentrate the separated micromolecules, solution in the product chamber or stream is collected and replaced with suitable solvent to ensure that electrophoresis can continue. [0060]
  • Preferably, at least one restriction membrane is formed as a composite or sandwich arrangement with at least two materials. Preferably, at least one restriction membrane is formed as a sandwich arrangement with at least two layers of material. In this preferred form, the sandwich arrangement includes an inner layer (facing the separation membrane in the first and second solvent streams, respectively) comprising a membrane having a pore size with a molecular mass cut-off less than the about 5000 Da and an outer layer comprising a membrane having a molecular mass cut-off of greater than about 5000 Da. [0061]
  • In a preferred form, the inner layer is made from an ultrafiltration, electrodialysis or haemodialysis material and the outer layer is made from polyacrylamide. In this preferred arrangement, the outer layer provides some structural support for the filtration membrane while preventing unwanted movement of fluid. The pore size of the filtration membrane is selected according to the size of the micromolecule to be separated such that the micromolecule cannot pass through the membrane. Typically, the molecular mass cut-off of the filtration membrane is between about 100 Da to 5000 Da. More preferably, the molecular mass cut-off is around 200 Da. [0062]
  • Hydrogel ion-permeable separation membranes (an ultrafiltration, electrodialysis and/or haemodialysis membranes coated with polyacrylamide) would be an alternative membrane type suitable for the present invention. Such membranes are possible to manufacture, but are currently not commercially available. [0063]
  • Preferably, the ion-permeable separation barrier is a membrane made from polyacrylamide and having a molecular mass cut-off from about 5 to 1000 kDa. The size of the separation membrane cut-off will depend on the sample being processed and the other molecules in the mixture. [0064]
  • The restriction barriers or membranes positioned adjacent the sample and product chambers can have the same molecular mass cut-off or different cut-offs therefore forming an asymmetrical arrangement. Typically, the restriction membrane separating the product chamber from the buffer compartment is formed in a sandwich configuration. [0065]
  • The distance between the electrodes can have an effect on the separation or movement of micromolecules through the barriers. It has been found that the shorter the distance between the electrodes, the faster the electrophoretic movement of micromolecules. A distance of about 6 cm has been found to be suitable for a laboratory scale apparatus. For scale up versions, the distance will depend on the number and type of separation membranes, the size and volume of the chambers for samples, buffers and separated products. Preferred distances would be in the order of 6 cm to about 10 cm. The distance will also relate to the voltage applied to the apparatus. The effect of the electric field is based on the equation: [0066]
  • e=V/d
  • (e=electric field, V=voltage, d=distance) [0067]
  • Therefore, smaller distances between the electrodes are preferred. Preferably, the distance between the electrodes should decrease in order to increase electric field strength, thereby further improving transfer rates. [0068]
  • Flow rate of sample/buffer can have an influence on the separation of micromolecules. Rates of milliliters per hour up to liters per hour can be used depending on the configuration of the apparatus and the sample to be separated. Currently in a laboratory scale instrument, the preferred flow rate is about 20±5 mL/min. However, flow rates ranging from about 0 to about 50,000 mL/min are also used across the various separation regimes. In some embodiments the maximum flow rate is higher, depending on the pumping means and size of the apparatus. The flow rate is dependent on the product to be transferred, efficiency of transfer, pre- and post-positioning with other applications. [0069]
  • Voltage and/or current applied can vary depending on the separation. Typically up to several thousand volts may be used but choice and variation of voltage will depend on the configuration of the apparatus, buffers and the sample to be separated. In a laboratory scale instrument, the preferred voltage is about 250 V. However, depending on transfer, efficiency, scale-up and particular method about 0 to about 5000 are used. Higher voltages may also be considered, depending on the apparatus and sample to be treated. [0070]
  • A number of first and second chambers could be stacked in the one apparatus for use in a scale-up device. [0071]
  • A single stream configuration can be produced where the second chamber forms a buffer chamber. In this configuration, contaminants would be moved out of the first chamber into the buffer compartments and the product of interest retained in the first chamber. In single stream configuration, the membranes can have either a symmetric or asymmetric arrangements. The present invention also includes these embodiments. [0072]
  • In use, a sample containing one or more micromolecules is added to the first chamber and an electric potential is applied to cause movement of at least one micromolecule from the sample through the separation membrane into the second chamber while the restriction membranes prevent movement of micromolecules from the first or the second chambers into the respective electrophoresis buffer chambers. Preferably, the micromolecule is removed and collected from the product chamber. [0073]
  • In a second aspect, the present invention provides a separation cartridge suitable for use in an electrophoresis apparatus for separating micromolecules, the cartridge comprising: [0074]
  • (a) a housing; [0075]
  • (b) an ion-permeable separation membrane having a defined molecular mass cut-off positioned in the housing; [0076]
  • (c) an ion-permeable restriction membrane positioned on either side of the separation membrane in the housing and spaced to form a first chamber and second chamber on either side of the separation membrane, wherein the restriction membrane is adapted to allow flow of ions into and out of the compartments and chambers under the influence of an electric field but substantially restrict movement of at least one micromolecule type from the second chamber. In a preferred embodiment, the cartridge further includes: [0077]
  • (d) electrodes positioned in the housing on the outer sides of the restriction barriers. [0078]
  • Preferably, the separation barrier is a membrane composed of polyacrylamide and having a molecular mass cut-off from about 5 to 1000 kDa. [0079]
  • Preferably, the ion-permeable separation membrane has a molecular mass cut-off greater than the molecular mass of the micromolecule to be separated. [0080]
  • At least one restriction membrane is preferably formed as a sandwich or composite arrangement of membranes with at least two materials. Preferably, the sandwich arrangement includes an inner layer comprising a restriction membrane having a pore size with a molecular mass cut-off less than about 5000 Da and an outer layer comprising a restriction membrane having a molecular mass cut-off of greater than about 5000 Da. [0081]
  • In a preferred form, the inner layer is made from an ultrafiltration, electrodialysis or haemodialysis material and the outer layer is made from polyacrylamide. In this preferred arrangement, the outer layer provides some structural support for the filtration membrane while preventing unwanted movement of fluid. The pore size of the filtration membrane is selected according to the size of the micromolecule to be separated such that the micromolecule cannot pass through the membrane. Typically, the molecular mass cut-off of the filtration membrane is between about 100 Da to 5000 Da. More preferably, the molecular mass cut-off is around 200 Da. [0082]
  • In a third aspect, the present invention provides a method of separating a micromolecule from a liquid sample, the method comprising: [0083]
  • (a) providing an electrophoresis apparatus according to the first aspect of the present invention; [0084]
  • (b) placing the sample in the first chamber of the apparatus; selecting a solvent for the first chamber having a pH such that the micromolecule to be separated is charged; [0085]
  • (c) applying an electric potential between the first and second chambers causing movement of micromolecules in the first chamber through the separation membrane into the second chamber while unwanted molecules are substantially prevented from entering the second chamber; [0086]
  • (d) optionally, periodically stopping and reversing the electric potential to cause movement of molecules having entered the separation membrane to move back into the first chamber, while substantially not causing any micromolecules that have entered the second chamber to re-enter first chamber; and [0087]
  • (e) maintaining steps (c) and optionally (d) until the desired amount of micromolecules are moved to the second chamber. [0088]
  • The micromolecule can be any micromolecule capable of receiving or having a charge. Examples include, but not limited to, biotin, Brilliant Blue FCF (BB FCF), azorubine, phytoestrogen, digoxigenin, hormones, cytokines, dyes, vitamins, chemicals, neutraceuticals, pharmaceuticals along with food and diet supplements. [0089]
  • The sample can contain one or more micromolecules of interest. Examples include, but are not limited to, crude extracts, microbial cultures, cell lysates, cellular products, chemical processing mixtures, cell culture media, plant products or extracts. [0090]
  • Solvent in the form of buffers that have been found to be particularly suitable for the method according to the present invention are Tris Borate around pH 9. It will be appreciated, however, that other buffers or solvents would also be suitable, depending on the separation. The concentration of the selected buffers can also influence or effect the movement of micromolecules through the separation barrier. Typically concentrations of about 10 mM to about 200 mM, more preferably 20 mM to 80 mM, have been found to be particularly suitable. Almost any buffers and/or solvents can be used with the present invention. The buffers and/or solvents that can be used are procedure/method/separation dependent. The concentration of the buffer and/or solvent is dependent upon the application/separation/procedure. [0091]
  • Reversal of current is an option but another embodiment is a resting period. Resting (a period without an electric potential being applied, but pumps remain on) is an optional step that can replace or be included before or after an optional electrical potential reversal. This reversal technique is often practised for protein separation work as an alternative to reversing the potential. [0092]
  • One benefit of the method according to the present invention is the possibility of scale-up without denaturing or adversely altering the physical or biological properties of the micromolecule. [0093]
  • In a fourth aspect, the present invention provides a micromolecule purified or separated by the method according to the third aspect of the present invention. [0094]
  • Preferably the micromolecule is less than 5000 Da. Examples include, but are not limited to, biotin, Brilliant Blue FCF (BB FCF), azorubine, phytoestrogen, digoxigenin, hormones, cytokines, dyes, vitamins, chemicals, neutraceuticals, pharmaceuticals along with food diet supplements, and combinations thereof. [0095]
  • In a fifth aspect, the present invention relates to use of the micromolecule according to the fourth aspect of the present invention in dietary, medical and veterinary applications. [0096]
  • Throughout this specification, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia before the priority date of each claim of this application. [0097]
  • In order that the present invention may be more clearly understood, preferred forms will be described with reference to the following drawings and examples. [0098]
  • MODES FOR CARRYING OUT THE INVENTION
  • The separation of micromolecules, molecules deemed to be less than about 5 kDa, was previously thought not to be possible using electrophoresis technology devised to separate macromolecules. This was due to the limit in pore size of membranes normally used in the systems. For example, the smallest cut-off produced in polyaccrylamide membranes is about 5 kDa which will retain any molecule larger than 5 kDa. The present invention results from modification of earlier technology to be capable of separating micromolecules by using some barriers or membranes other than polyacrylamide membranes traditionally used. It has been found that when commercially available membranes in the form of ultrafiltration, electrodialysis and haemodialysis membranes are used as separation or restriction membranes, the size of molecule that can be dealt with, is significantly smaller than previously thought. [0099]
  • In order to separate and purify micromolecules, hydrogel polyacrylamide membranes traditionally used in the earlier system's cartridge were placed as backing to a commercial membrane with the desired pore size. The polyacrylamide membrane is useful to prevent unregulated fluid movement across the membranes, whilst the commercial membrane is used to retain the smaller molecular species within the sample or product streams or chambers. The membranes used for this work were Pall Gelman Omega ultrafiltration membranes. These ultrafiltration membranes are available commercially with pore sizes ranging from hundreds of kDa down to 1000 Da. [0100]
  • Another surprising finding was that the relative pore size of the ultrafiltration membranes was found to be different when used in the sandwich arrangement than when used in an ultrafiltration unit. The relative pore size appears to be smaller than the stated size. Thus it has been shown to be possible to retain molecules as small as 200 Dalton within the modified system. [0101]
  • When an apparatus is operated with the traditional polyacrylamide membranes used for macromolecule purification or separation, small molecules under 5 kDa tend to transfer from the sample stream into the product stream where they remain transiently. These molecules then move through the bottom restriction membrane into the buffer stream where they are lost. [0102]
  • Experiments were carried out on several model molecules which have varied structure and function. The use of these micromolecules demonstrates that a wide variety of molecules could be used within the system. Two molecules studied were Bis[4-(N-ethyl-N-3-sulfophenylmethyl)aminophenyl]-2-sulfophenylmethylium disodium salt (Brilliant Blue FCF) which has a molecular mass of 793 Dalton, and Disodium 2-(4-Sulfo-1Napthylazo)-1-Napthol-4-Sulfonate (Azorubine) which has a molecular mass of 502 Dalton. Two other molecules were also investigated, one being Vitamin H (Biotin) and the other a small phytoestrogen separated from red leaf clover (supplied by Novogen, Sydney Australia). Brilliant Blue FCF and Azorubine are two chemicals currently used in the food industry as colouring agents. Biotin has several uses, first as a necessary vitamin in the human diet and secondly, but not insignificantly, as a labelling agent in scientific assays. Phytoestrogens are separated commercially from many sources primarily soy and clover where they are made into herbal and pharmaceutical medicines. [0103]
  • Experiments using Brilliant Blue FCF (BB-FCF), Azorubine, Biotin and a Phytoestrogen all confirmed that standard polyacrylamide electrophoresis membranes do not retain these micromolecules during a separation. These molecules are very small and definitely considered micromolecules; BB-FCF (793 Da), Azorubine (502 Da), Biotin (244 Da) and a Phytoestrogen (˜200 Da). [0104]
  • Experiments using BB-FCF and Azorubine with a pH 9.0 buffer and a cartridge sandwich of 5-5-5 kDa polyacrylamide membranes ([0105] upper restriction 5 kDa, separation membrane 5 kDa, lower restriction 5 kDa) showed that complete transfer from the sample stream occurs in a short period of time. The macromolecules build slightly in the product stream before passing completely into the buffer stream where they are diluted so highly that they are lost to analysis. This is also true for the Phytoestrogen and for Biotin.
  • FIGS. 1, 2, [0106] 3, and 4 show the transient build up and eventual loss of BB-FCF, Azorubine, Biotin, and the Phytoestrogen, within the an apparatus used for macromolecule separation having only polyacrylamide membranes. The time taken for the micromolecules to completely transfer out of the system varies for each molecule. It is likely that this is due to the difference in charge to mass ratios between the molecules.
  • Use of traditional polyacrylamide membranes was therefore found not a feasible method for the separation of molecules under about 5 kDa. This led to the novel step of trialing new membranes, previously not considered useful for prior art systems. These commercially available membranes are manufactured to be used under conditions of high pressure where they act purely as a filter. This means that the membranes are not always “water tight” when used in the earlier system. Only those membranes with a very small pore size retain liquid under the low pressures used in the earlier system. These ultrafiltration membranes are ideal for use in a preparative electrophoresis system unless they are backed with a membrane designed to stop or reduce transfer of liquid but allow ion and charged molecule transfer under an electric filed. [0107]
  • It was found that alternative membrane types could be used when they were backed with a hydrogel membrane to give fluid retention. This double layering not only prevented fluid leakage across the membranes but also significantly reduced the levels of endo-osmosis produced. Endo-osmosis levels are a big consideration in the design and use of membranes for preparative electrophoresis systems. Particular chemistries of membranes can produce such large changes in fluid volumes from one stream to another via electro-endo-osmosis so cannot be used. [0108]
  • The separation and retention of very small molecules was made possible in the apparatus according to the present invention by using a small pore sized ultrafiltration membrane (Pall Gelman Omega) as the bottom restriction in combination with a polyacrylamide membrane. The use of a 1 kDa Omega ultrafiltration membrane in this position allowed the capture of molecules as small as 200 Da. Experiments were carried out again using BB-FCF, Azorubine, Biotin and a Phytoestrogen. [0109]
  • The following cartridge configuration was used for the separations: [0110]
  • 5 kDa polyacrylamide restriction membrane [0111]
  • Support Grid [0112]
  • 10 kDa polyacrylamide separation membrane [0113]
  • Support Grid [0114]
  • 1 kDa ultrafiltration restriction membrane [0115]
  • 5 kDa polyacrylamide restriction membrane [0116]
  • It was possible to move BB-FCF, Azorubine and Biotin using the above cartridge configuration from the sample stream to the product stream where they were trapped and collected. The Phytoestrogen experiments used a 5 kDa ultrafiltration membrane to retain the molecules in the product stream. [0117]
  • Brilliant Blue FCF was readily transferred and retained in the product stream with the use of the 1 kDa Omega ultrafiltration membrane. This molecule is only 793 Da and so retention with a 1000 Da membrane would not be expected. The BB-FCF separation is represented by FIG. 5. Analysis of the BB-FCF separation was carried out using the absorbance at 630 nm. [0118]
  • Azorubine was moved across the separation membrane and collected in the product stream. Using a pH 9.0 Tris-Borate buffer 83% of the Azorubine was transferred from the sample stream to the product stream within 45 minutes. This transfer was measured using the absorbance of Azorubine at 516 nm. The separation is illustrated in FIG. 4. [0119]
  • The Biotin separation utilised a pH 9.0 buffer with the same cartridge configuration as that used for the BB-FCF and Azorubine. The transfer of this molecule was monitored using the absorbance at 230 nm. This experiment showed that the 1 kDa ultrafiltration membrane used could retain molecules as small as 244 Dalton. FIG. 7 shows that over 80% of the Biotin was transferred to the product stream where it was contained. The phytoestrogen transfer experiment depicted in FIG. 8 showed the movement and successful capture of phytoestrogen. The decrease over time after the initial high levels of phytoestrogen are most likely due to the fact that a 5 kDa ultrafiltration membrane was used as the bottom restriction membrane. The use of a 1 kDa ultrafiltration membrane would help to completely retain the small phytoestrogen. [0120]
  • Not only could Azorubine and BB-FCF be moved across a separation membrane from sample stream to the product stream, these two molecules could also be separated from each other. With only 293 Da difference in size, the two compounds were separated from each other using a size exclusion separation where the largest molecule was retained in the product stream whilst the smaller molecule was allowed to transfer through into the buffer stream. The following cartridge configuration was used for the separation: [0121]
  • 5 kDa polyacrylamide restriction membrane [0122]
  • Support Grid [0123]
  • 3 kDa ultrafiltration separation membrane [0124]
  • 5 kDa polyacrylamide separation membrane [0125]
  • Support Grid [0126]
  • 1 kDa ultrafiltration restriction membrane [0127]
  • 5 kDa polyacrylamide restriction membrane [0128]
  • BB-FCF was separated from Azorubine. By allowing Azorubine to pass through the 3 kDa ultrafiltration membrane whilst retaining the BB-FCF in the sample stream, an adequate separation was achieved. The concentration of Azorubine decreased significantly from the sample stream but did not build up substantially in the product stream. This was due to loss into the buffer stream over time. The BB-FCF can pass through a 3 kDa membrane but only very slowly so separation of the two molecules was achieved. The movement of both molecules was monitored using 603 nm for BB-FCF and 516 nm for Azorubine. FIG. 9 shows the selective nature of the separation. [0129]
  • To improve the separation of BB-FCF from Azorubine a different cartridge configuration was utilised as follows: [0130]
  • 5 kDa polyacrylamide restriction membrane [0131]
  • Support Grid [0132]
  • 200 kDa polyacrylamide separation membrane [0133]
  • Support Grid [0134]
  • 1 kDa ultrafiltration restriction membrane [0135]
  • 5 kDa polyacrylamide restriction membrane [0136]
  • This separation allowed both molecules to quickly transfer to the product stream from the sample stream. Then over time the Azorubine passed into the buffer stream, whilst the BB-FCF was retained. The fact that the Azorubine would transfer through the 1 kDa Omega ultrafiltration membrane enabled separation of Azorubine from BB-FCF more effectively than previously. FIG. 10 shows that after a three hour separation close to 74% of the BB-FCF was still present in the downstream whilst only 15% of the Azorubine remained. This separation shows the highly selective nature of the separation, which opens many possibilities for its use with a number of different molecular separations. [0137]
  • In new electrophoresis system it has been found that micromolecules under 5 kDa can be separated with this technology. When the polyacrylamide membranes are used in combination with certain commercially available membranes, molecules as small as ˜200 Da can be separated and purified. [0138]
  • There were several problems encountered in the separation of micromolecules using an unmodified electrophoresis system. Difficulty retaining micromolecules in the system has been overcome with the addition of combinations of membranes. However, these membranes themselves posed problems in that they are not designed to retain liquids and can produce large levels of electro-endo-osmosis. The liquid retention problem has been solved by backing the membranes with the hydrogel polyacrylamide membranes, which also helped to reduce the electro-endo-osmosis levels. [0139]
  • Several examples demonstrating the capability of the present invention in separating macromolecules have been shown though many other possible micromolecules of commercial interest do exist. For example this technology could be used in the separation and purification of cytokines and growth factors for use in the pharmaceutical and research industries. Currently cytokines and growth factors account for over 50% of the biotechnology based pharmaceutical product sales. Other areas where the use of the present technology could improve current separation strategies and be of substantial commercial benefit include purification of pharmaceutical drugs, food additives, agro-chemicals and fine chemicals. [0140]
  • It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive. [0141]

Claims (32)

1. An electrophoretic separation apparatus for separating micromolecules, the apparatus comprising:
(a) an anode;
(b) a cathode disposed relative to the anode so as to be adapted to generate an electric field in an electric field area therebetween upon application of a voltage potential between the anode and the cathode;
(c) a separation membrane disposed in the electric field area;
(d) a first restriction membrane disposed between the anode and the separation membrane so as to define a first interstitial volume therebetween;
(e) a second restriction membrane disposed between the cathode and the separation membrane so as to define a second interstitial volume therebetween; and
(f) means adapted to provide a sample constituent in a selected one of the first and second interstitial volumes;
wherein upon application of the voltage potential, a selected separation product is removed from the sample constituent, thorough the separation membrane, and provided to the other of the first and second interstitial volumes and wherein a micromolecule is capable of being retained in at least one of the interstitial volumes.
2. The apparatus according to claim 1 wherein at least one restriction membrane is formed as a composite arrangement with at least two materials.
3. The electrophoretic separation apparatus of claim 1 wherein at least one of the restriction membranes is comprised of at least two membranes having distinctive pores sizes.
4. An apparatus for electrophoretic separation of micromolecules, the apparatus comprising:
(a) an anode buffer compartment and a cathode buffer compartment;
(b) electrodes positioned in the buffer compartments;
(c) a first chamber and a second chamber positioned on either side of an ion-permeable separation membrane having a defined molecular mass cut-off, the first chamber and the second chamber being positioned between the anode and the cathode buffer compartments and separated by an ion-permeable restriction membrane positioned on at least one side of the separation membrane, the restriction membrane allowing flow of ions into and out of the compartments and chambers under the influence of an electric field but substantially restrict movement of at least one micromolecule type from the second chamber into the buffer compartment.
5. The apparatus according to claim 4 wherein the ion-permeable separation membrane has a molecular mass cut-off greater than the molecular mass of the micromolecule to be separated.
6. The apparatus according to claim 4 wherein at least one buffer compartment, sample chamber or product chamber is configured to allow flow of the respective buffer, sample or product solution to form a stream.
7. The apparatus according to claim 4 wherein at least one restriction membrane is formed as a composite arrangement with at least materials.
8. The apparatus according to claim 4 wherein at least one restriction barrier is formed as a sandwich arrangement with at least two layers of material.
9. The apparatus according to claim 8 wherein the sandwich arrangement includes an inner layer comprising a membrane having a pore size with a molecular mass cut-off less than the about 5000 Da and an outer layer comprising a membrane having a molecular mass cut-off of greater than about 5000 Da.
10. The apparatus according to claim 9 wherein the inner layer is made from an ultrafiltration, electrodialysis or haemodialysis membrane material and the outer layer is a membrane material made from polyacrylamide.
11. The apparatus according to claim 10 wherein the ultrafiltration membrane has a molecular mass cut-off between 100 Da and 5000 Da.
12. The apparatus according to claim 11 wherein the ultrafiltration membrane has a molecular mass cut-off of about 1 kDa.
13. The apparatus according to claim 4 wherein the ion-permeable separation membrane is made from polyacrylamide and having a molecular mass cut-off from 5 to 1000 kDa.
14. A separation cartridge suitable for use in an electrophoretic separation apparatus for separating micromolecules, the cartridge comprising:
(a) a housing;
(b) an ion-permeable separation membrane having a defined molecular mass cut-off positioned in the housing;
(c) an ion-permeable restriction membrane positioned either side of the separation membrane in the housing and spaced to form a first chamber and second chamber on either side of the separation membrane, wherein the restriction membrane is adapted to allow flow of ions into and out of the compartments and chambers under the influence of an electric field but substantially restrict movement of at least one micromolecule type from the second chamber.
15. The cartridge according to claim 14 further including:
(d) electrodes positioned in the housing on the outer sides of the restriction barriers.
16. The apparatus according to claim 14 wherein the ion-permeable separation membrane has a molecular mass cut-off greater than the molecular mass of a micromolecule to be separated.
17. The cartridge according to claim 14 wherein the separation membrane is composed of polyacrylamide and having a molecular mass cut-off from about 5 to 1000 kDa.
18. The cartridge according to claim 14 wherein at least one restriction membrane is formed as a composite arrangement with at least two materials.
19. The cartridge according to claim 14 wherein at least one restriction membrane is formed as a sandwich arrangement of membranes with at least two layers of material.
20. The cartridge according to claim 19 wherein the sandwich arrangement includes an inner layer comprising a membrane having a pore size with a molecular mass cut-off less than the about 5000 Da and an outer layer comprising a membrane having a molecular mass cut-off of greater than about 5000 Da.
21. The cartridge according to claim 19 wherein the inner layer is made from an ultrafiltration, electrodialysis or haemodialysis membrane material and the outer layer is a membrane material made from polyacrylamide.
22. The cartridge according to claim 20 wherein the ultrafiltration membrane has a molecular mass cut-off between 100 Da and 5000 Da.
23. The cartridge according to claim 22 wherein the ultrafiltration membrane has a molecular mass cut-off of about 1 kDa.
24. The cartridge according to claim 23 wherein the ion-permeable separation barrier is a membrane made from polyacrylamide and having a molecular mass cut-off from 5 to 1000 kDa.
25. A method of separating a micromolecule from a liquid sample, the method comprising:
(a) providing an electrophoresis apparatus according to clam 4;
(b) placing the sample in the first chamber of the apparatus;
(c) selecting a solvent for the first chamber having a pH such that the micromolecule to be separated is charged;
(d) applying an electric potential between the first and second chambers causing movement of micromolecules in the first stream through the separation membrane into the second chamber while unwanted molecules are substantially prevented from entering the second chamber;
(e) optionally, periodically stopping and reversing the electric potential to cause movement of molecules having entered the separation membrane to move back into the first chamber, while substantially not causing any micromolecules that have entered the second chamber to re-enter first chamber; and
(f) maintaining steps (d) and optionally (e) until the desired amount of micromolecules are moved to the second chamber.
26. The method according to claim 25 wherein the micromolecule is selected from the group consisting of biotin, Brilliant Blue FCF (BB FCF), azorubine, phytoestrogen, digoxigenin, hormones, cytokines, dyes, vitamins, chemicals, neutraceuticals, pharmaceuticals food diet supplements, and combinations thereof.
27. The method according to claim 25 wherein the sample is selected from the group consisting of crude extracts, microbial cultures, cell lysates, cellular products, chemical processing mixtures, cell culture media, plant products or extracts.
28. The method according to claim 25 wherein the solvent is Tris Borate buffer around pH 9.
29. The method according to claim 28 wherein buffer has a concentration of 10 mM to 200 mM.
30. The method according to claim 29 wherein the buffer has a concentration of 20 mM to 80 mM.
31. A micromolecule purified or separated by the method according to claim 25.
32. The micromolecule according to claim 31 selected from the group consisting of biotin, Brilliant Blue FCF (BB FCF), azorubine, phytoestrogen, digoxigenin, hormones, cytokines, dyes, vitamins, chemicals, neutraceuticals, pharmaceuticals, food supplements, and combinations thereof.
US10/265,798 2000-04-14 2002-10-07 Separation of micromolecules Abandoned US20030029725A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/265,798 US20030029725A1 (en) 2000-04-14 2002-10-07 Separation of micromolecules

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPQ6914A AUPQ691400A0 (en) 2000-04-14 2000-04-14 Separation of micromolecules
AUPQ6914 2000-04-14
US09/834,462 US6660150B2 (en) 2000-04-14 2001-04-13 Separation of micromolecules
US10/265,798 US20030029725A1 (en) 2000-04-14 2002-10-07 Separation of micromolecules

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/834,462 Division US6660150B2 (en) 2000-04-14 2001-04-13 Separation of micromolecules

Publications (1)

Publication Number Publication Date
US20030029725A1 true US20030029725A1 (en) 2003-02-13

Family

ID=25646299

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/834,462 Expired - Fee Related US6660150B2 (en) 2000-04-14 2001-04-13 Separation of micromolecules
US10/265,798 Abandoned US20030029725A1 (en) 2000-04-14 2002-10-07 Separation of micromolecules

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/834,462 Expired - Fee Related US6660150B2 (en) 2000-04-14 2001-04-13 Separation of micromolecules

Country Status (3)

Country Link
US (2) US6660150B2 (en)
AU (1) AUPQ691400A0 (en)
WO (1) WO2001078876A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080067070A1 (en) * 2003-05-15 2008-03-20 Dennis Rylatt Cell Separation
US20090101507A1 (en) * 2003-10-07 2009-04-23 Aitken Robert J Sperm cell separation by electrophoresis

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078877A1 (en) * 2000-04-18 2001-10-25 Gradipore Limited Electrophoresis separation and treatment of samples
WO2002093168A1 (en) * 2001-05-15 2002-11-21 Gradipore Limited Prion diagnostic test
US9475709B2 (en) 2010-08-25 2016-10-25 Lockheed Martin Corporation Perforated graphene deionization or desalination
US9766207B2 (en) 2011-11-04 2017-09-19 Bio-Rad Laboratories, Inc. Affinity methods and compositions employing electronic control of pH
US9234875B2 (en) 2011-11-04 2016-01-12 Bio-Rad Laboratories, Inc. Simultaneous purification of cell components
EP2814597A4 (en) 2012-02-15 2015-10-28 Bio Rad Laboratories Electronic control of ph and ionic strength
US9321012B2 (en) 2012-04-04 2016-04-26 Bio-Rad Laboratories, Inc. Electronic protein fractionation
US10376845B2 (en) 2016-04-14 2019-08-13 Lockheed Martin Corporation Membranes with tunable selectivity
US9610546B2 (en) 2014-03-12 2017-04-04 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US10653824B2 (en) 2012-05-25 2020-05-19 Lockheed Martin Corporation Two-dimensional materials and uses thereof
US9834809B2 (en) 2014-02-28 2017-12-05 Lockheed Martin Corporation Syringe for obtaining nano-sized materials for selective assays and related methods of use
US9844757B2 (en) 2014-03-12 2017-12-19 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US9744617B2 (en) 2014-01-31 2017-08-29 Lockheed Martin Corporation Methods for perforating multi-layer graphene through ion bombardment
US10017852B2 (en) 2016-04-14 2018-07-10 Lockheed Martin Corporation Method for treating graphene sheets for large-scale transfer using free-float method
US9592475B2 (en) 2013-03-12 2017-03-14 Lockheed Martin Corporation Method for forming perforated graphene with uniform aperture size
US9572918B2 (en) 2013-06-21 2017-02-21 Lockheed Martin Corporation Graphene-based filter for isolating a substance from blood
SG11201606287VA (en) 2014-01-31 2016-08-30 Lockheed Corp Processes for forming composite structures with a two-dimensional material using a porous, non-sacrificial supporting layer
CN105940479A (en) 2014-01-31 2016-09-14 洛克希德马丁公司 Methods for perforating two-dimensional materials using a broad ion field
CA2973472A1 (en) 2014-09-02 2016-03-10 Lockheed Martin Corporation Hemodialysis and hemofiltration membranes based upon a two-dimensional membrane material and methods employing same
EP3303582A1 (en) 2015-06-01 2018-04-11 Qiagen GmbH Electrophoresis assisted method and device for purifying a charged target molecule from a sample
JP2018528144A (en) 2015-08-05 2018-09-27 ロッキード・マーチン・コーポレーション Perforable sheet of graphene-based material
AU2016303049A1 (en) 2015-08-06 2018-03-01 Lockheed Martin Corporation Nanoparticle modification and perforation of graphene
SG11201808961QA (en) 2016-04-14 2018-11-29 Lockheed Corp Methods for in situ monitoring and control of defect formation or healing
WO2017180134A1 (en) 2016-04-14 2017-10-19 Lockheed Martin Corporation Methods for in vivo and in vitro use of graphene and other two-dimensional materials
WO2017180141A1 (en) 2016-04-14 2017-10-19 Lockheed Martin Corporation Selective interfacial mitigation of graphene defects
SG11201809015WA (en) 2016-04-14 2018-11-29 Lockheed Corp Two-dimensional membrane structures having flow passages

Citations (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878564A (en) * 1972-04-14 1975-04-22 Shang J Yao Blood and tissue detoxification method
US4036748A (en) * 1974-04-19 1977-07-19 Bayer Aktiengesellschaft Asymmetric, semipermeable membranes of polybenz-1,3-oxazine diones-(2,4)
US4045455A (en) * 1974-01-03 1977-08-30 Bayer Aktiengesellschaft Process for separating 1,5-dinitroanthraquinone and 1,8-dinitroanthraquinone from dinitroanthraquinone mixtures
US4045337A (en) * 1974-06-28 1977-08-30 Bayer Aktiengesellschaft Asymmetric, semipermeable membranes of cyclic polyureas
US4069215A (en) * 1975-08-16 1978-01-17 Bayer Aktiengesellschaft Semipermeable membranes of sulphonated polybenz-1,3-oxazin-2,4-diones
US4115225A (en) * 1977-07-22 1978-09-19 Ionics, Inc. Electrodialysis cell electrode reversal and anolyte recirculation system
US4123342A (en) * 1976-03-25 1978-10-31 Aqua-Chem, Inc. Ultrafiltration and electrodialysis method and apparatus
US4174439A (en) * 1977-05-04 1979-11-13 Bayer Aktiengesellschaft Process for isolating glucopyranose compound from culture broths
US4196304A (en) * 1977-03-26 1980-04-01 Bayer Aktiengesellschaft Separation of stereoisomeric cyclic carboxylic acids
US4204929A (en) * 1978-04-18 1980-05-27 University Patents, Inc. Isoelectric focusing method
US4217227A (en) * 1975-12-06 1980-08-12 Bayer Aktiengesellschaft Semipermeable membranes of copolyamides
US4238306A (en) * 1979-02-14 1980-12-09 Research Products Rehovot Ltd. Electrodialysis process for the separation of non-essential amino acids from derivatives thereof
US4238307A (en) * 1979-02-14 1980-12-09 Research Products Rehovot Ltd. Electrodialysis process for the separation of essential amino acids from derivatives thereof
US4252652A (en) * 1977-09-16 1981-02-24 Bayer Aktiengesellschaft Process of using a semi-permeable membrane of acrylonitrile copolymers
US4259079A (en) * 1978-04-21 1981-03-31 Blum Alvin S Method and apparatus for electrical separation of molecules
US4269967A (en) * 1976-09-24 1981-05-26 Bayer Aktiengesellschaft Semipermeable membranes of aromatic disulfimide containing polyamides
US4276140A (en) * 1980-01-10 1981-06-30 Ionics Inc. Electrodialysis apparatus and process for fractionating protein mixtures
US4279724A (en) * 1979-07-18 1981-07-21 Hearn Milton T W Preparative electrofocusing in flat bed granulated polysaccharide gels
US4299677A (en) * 1980-11-03 1981-11-10 The Hubinger Co. Process for the preferential separation of fructose from glucose
US4322275A (en) * 1980-01-10 1982-03-30 Ionics Incorporated Fractionation of protein mixtures
US4362612A (en) * 1978-04-18 1982-12-07 University Patents, Inc. Isoelectric focusing apparatus
US4376023A (en) * 1980-11-03 1983-03-08 The Hubinger Company Process for the preferential separation of dextrose from oligosaccharides
US4383923A (en) * 1980-07-02 1983-05-17 Bayer Aktiengesellschaft Semipermeable membranes
US4396477A (en) * 1981-06-29 1983-08-02 Ionics, Incorporated Separation of proteins using electrodialysis-isoelectric focusing combination
US4441978A (en) * 1981-06-29 1984-04-10 Ionics Incorporated Separation of proteins using electrodialysis - isoelectric focusing combination
US4533447A (en) * 1983-06-13 1985-08-06 Meldon Jerry H Apparatus for and method of isoelectric focussing
US4608140A (en) * 1985-06-10 1986-08-26 Ionics, Incorporated Electrodialysis apparatus and process
US4661224A (en) * 1984-11-26 1987-04-28 Ionics, Incorporated Process and apparatus for electrically desorbing components selectively sorbed on an electrolytically conducting barrier
US4673483A (en) * 1986-03-20 1987-06-16 Ionics Incorporated Isoelectric focusing apparatus
US4711722A (en) * 1983-10-12 1987-12-08 Ajinomoto Co., Inc. Method for preventing fouling of electrodialysis membrane
US4746647A (en) * 1984-05-28 1988-05-24 Stefan Svenson Purifying protein or peptide recombinant DNA products by electroseparation
US4780411A (en) * 1984-09-22 1988-10-25 Bayer Aktiengesellschaft Water-absorbing, essentially water-free membrane for reagent substrates and methods of preparing the same
US4897169A (en) * 1986-08-18 1990-01-30 Milan Bier Process and apparatus for recycling isoelectric focusing and isotachophoresis
US4963236A (en) * 1989-03-08 1990-10-16 Ampholife Technologies Apparatus and methods for isoelectric focusing
US5015388A (en) * 1988-03-25 1991-05-14 Hospal Industrie Integrated device for the biospecific purification of a liquid containing cellular elements
US5043048A (en) * 1987-07-17 1991-08-27 Muralidhara Harapanahalli S Electromembrane apparatus and process for preventing membrane fouling
US5080770A (en) * 1989-09-11 1992-01-14 Culkin Joseph B Apparatus and method for separating particles
US5082548A (en) * 1987-04-11 1992-01-21 Ciba-Geigy Corporation Isoelectric focusing apparatus
US5087338A (en) * 1988-11-15 1992-02-11 Aligena Ag Process and device for separating electrically charged macromolecular compounds by forced-flow membrane electrophoresis
US5096547A (en) * 1990-06-23 1992-03-17 Bayer Aktiengesellschaft Preparation of chromic acid using bipolar membranes
US5114555A (en) * 1988-01-05 1992-05-19 Monsanto Company Continuous isoelectric separation
US5127999A (en) * 1989-04-06 1992-07-07 Bayer Aktiengesellschaft Process for the preparation of alkali metal dichromates and chromic acid by electrolysis
US5160594A (en) * 1989-03-08 1992-11-03 Board Of Regents Of The University Of Texas System Apparatus and methods for isoelectric focusing of amphoteric substances incorporating ion selective membranes in electrode chambers
US5173164A (en) * 1990-09-11 1992-12-22 Bioseparations, Inc. Multi-modality electrical separator apparatus and method
US5185086A (en) * 1991-07-16 1993-02-09 Steven Kaali Method and system for treatment of blood and/or other body fluids and/or synthetic fluids using combined filter elements and electric field forces
US5238570A (en) * 1991-10-31 1993-08-24 Bayer Aktiengesellschaft Asymmetric semipermeable membranes of aromatic polycondensates, processes for their preparation and their use
US5277774A (en) * 1991-06-26 1994-01-11 Shmidt Joseph L Free flow electrophoresis method
US5336387A (en) * 1990-09-11 1994-08-09 Bioseparations, Inc. Electrical separator apparatus and method of counterflow gradient focusing
US5340449A (en) * 1990-12-07 1994-08-23 Shukla Ashok K Apparatus for electroelution
US5352343A (en) * 1990-10-06 1994-10-04 The University Of Bradford Separation of the components of liquid dispersions
US5407553A (en) * 1992-12-08 1995-04-18 Osmotek Inc. Turbulent flow electrodialysis cell
US5420047A (en) * 1992-11-13 1995-05-30 Bayer Aktiengesellschaft Method for carrying out immunodiagnostic tests
US5437774A (en) * 1993-12-30 1995-08-01 Zymogenetics, Inc. High molecular weight electrodialysis
US5441646A (en) * 1991-08-22 1995-08-15 Bayer Aktiengesellschaft Process of removing sulfate ions from water with a poly(meth)acrylamide exchange resin
US5490939A (en) * 1994-03-03 1996-02-13 Bayer Aktiengesellschaft Process for reconcentrating overspray from one-component coating compositions
US5504239A (en) * 1993-06-14 1996-04-02 Bayer Aktiengesellschaft Process for separating off alkanols from other organic compounds of higher carbon number
US5503744A (en) * 1993-10-07 1996-04-02 Sanyo Electric Co., Ltd. Biological oscillating device
US5558753A (en) * 1994-05-20 1996-09-24 U.S. Filter/Ionpure, Inc. Polarity reversal and double reversal electrodeionization apparatus and method
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
US5565102A (en) * 1993-11-09 1996-10-15 Bayer Aktiengesellschaft Process for purifying organic synthesis products
US5610285A (en) * 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5662813A (en) * 1994-10-21 1997-09-02 Bioseparations, Inc. Method for separation of nucleated fetal erythrocytes from maternal blood samples
US5723031A (en) * 1994-10-31 1998-03-03 Bayer Aktiengesellschaft Method for the analytical separation of viruses
US5733442A (en) * 1990-12-07 1998-03-31 Shukla; Ashok K. Microdialysis/Microelectrodialysis system
US5868938A (en) * 1995-12-11 1999-02-09 Bayer Aktiengesellschaft Chiral stationary phases for chromatographic separation of optical isomers
US5869275A (en) * 1998-07-20 1999-02-09 Huang; Eric Z. Affinity ultrafiltration assay for transferase activity
US5891736A (en) * 1996-06-21 1999-04-06 Bayer Corporation Reagents and methods for releasing and measuring lead ions from biological matrices
US5938904A (en) * 1996-03-27 1999-08-17 Curagen Corporation Separation of charged particles by a spatially and temporally varying electric field
US5986075A (en) * 1999-01-20 1999-11-16 Bayer Corporation Process for the production of diazonium compounds with a low content of sodium ions
US6093296A (en) * 1990-02-28 2000-07-25 Aclara Biosciences, Inc. Method and device for moving molecules by the application of a plurality of electrical fields
US6117297A (en) * 1995-03-23 2000-09-12 Ionics, Incorporated Electrodialysis apparatus
US6129842A (en) * 1995-12-15 2000-10-10 Bayer Aktiengesellschaft Multiphase extractor
US6171825B1 (en) * 1997-04-18 2001-01-09 Bayer Corporation Preparation of recombinant factor VIII in a protein free medium
US6284115B1 (en) * 1999-09-21 2001-09-04 Agilent Technologies, Inc. In-line flow through micro-dialysis apparatus and method for high performance liquid phase separations
US6328869B1 (en) * 1998-09-07 2001-12-11 Gradipore Limited Apparatus for macromolecule purification
US20010052462A1 (en) * 2000-04-18 2001-12-20 David Ogle Small separation apparatus
US6402913B1 (en) * 1999-04-12 2002-06-11 Gradipore Limited Separation of plasma components
US20030213748A1 (en) * 2000-09-14 2003-11-20 Juzer Jangbarwala Electrophoretic cross-flow membrane filter system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381232A (en) 1981-08-24 1983-04-26 Ionics, Incorporated Multi-stage electrodialysis stack electrode reversal system and method of operation
JPS58147639A (en) 1982-02-26 1983-09-02 Hideyuki Nishizawa Separation by continuous electric migration and its device
DE4116179A1 (en) 1991-05-17 1992-11-19 Serva Feinbiochem Gmbh & Co ELECTROPHORESE CHAMBER
US6446815B2 (en) 1995-10-19 2002-09-10 Bayer Aktiengesellschaft Multiple phase extractor
DE19646950A1 (en) 1996-11-13 1998-05-14 Bayer Ag Electrochemical gas diffusion half cell
JP2001517148A (en) 1997-04-02 2001-10-02 バイエル・アクチエンゲゼルシヤフト A method for transferring substances between two liquid phases.

Patent Citations (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878564A (en) * 1972-04-14 1975-04-22 Shang J Yao Blood and tissue detoxification method
US4045455A (en) * 1974-01-03 1977-08-30 Bayer Aktiengesellschaft Process for separating 1,5-dinitroanthraquinone and 1,8-dinitroanthraquinone from dinitroanthraquinone mixtures
US4036748A (en) * 1974-04-19 1977-07-19 Bayer Aktiengesellschaft Asymmetric, semipermeable membranes of polybenz-1,3-oxazine diones-(2,4)
US4045337A (en) * 1974-06-28 1977-08-30 Bayer Aktiengesellschaft Asymmetric, semipermeable membranes of cyclic polyureas
US4069215A (en) * 1975-08-16 1978-01-17 Bayer Aktiengesellschaft Semipermeable membranes of sulphonated polybenz-1,3-oxazin-2,4-diones
US4217227A (en) * 1975-12-06 1980-08-12 Bayer Aktiengesellschaft Semipermeable membranes of copolyamides
US4123342A (en) * 1976-03-25 1978-10-31 Aqua-Chem, Inc. Ultrafiltration and electrodialysis method and apparatus
US4269967A (en) * 1976-09-24 1981-05-26 Bayer Aktiengesellschaft Semipermeable membranes of aromatic disulfimide containing polyamides
US4196304A (en) * 1977-03-26 1980-04-01 Bayer Aktiengesellschaft Separation of stereoisomeric cyclic carboxylic acids
US4174439A (en) * 1977-05-04 1979-11-13 Bayer Aktiengesellschaft Process for isolating glucopyranose compound from culture broths
US4115225A (en) * 1977-07-22 1978-09-19 Ionics, Inc. Electrodialysis cell electrode reversal and anolyte recirculation system
US4252652A (en) * 1977-09-16 1981-02-24 Bayer Aktiengesellschaft Process of using a semi-permeable membrane of acrylonitrile copolymers
US4362612A (en) * 1978-04-18 1982-12-07 University Patents, Inc. Isoelectric focusing apparatus
US4204929A (en) * 1978-04-18 1980-05-27 University Patents, Inc. Isoelectric focusing method
US4259079A (en) * 1978-04-21 1981-03-31 Blum Alvin S Method and apparatus for electrical separation of molecules
US4238307A (en) * 1979-02-14 1980-12-09 Research Products Rehovot Ltd. Electrodialysis process for the separation of essential amino acids from derivatives thereof
US4238306A (en) * 1979-02-14 1980-12-09 Research Products Rehovot Ltd. Electrodialysis process for the separation of non-essential amino acids from derivatives thereof
US4279724A (en) * 1979-07-18 1981-07-21 Hearn Milton T W Preparative electrofocusing in flat bed granulated polysaccharide gels
US4276140A (en) * 1980-01-10 1981-06-30 Ionics Inc. Electrodialysis apparatus and process for fractionating protein mixtures
US4322275A (en) * 1980-01-10 1982-03-30 Ionics Incorporated Fractionation of protein mixtures
US4383923A (en) * 1980-07-02 1983-05-17 Bayer Aktiengesellschaft Semipermeable membranes
US4299677A (en) * 1980-11-03 1981-11-10 The Hubinger Co. Process for the preferential separation of fructose from glucose
US4376023A (en) * 1980-11-03 1983-03-08 The Hubinger Company Process for the preferential separation of dextrose from oligosaccharides
US4396477A (en) * 1981-06-29 1983-08-02 Ionics, Incorporated Separation of proteins using electrodialysis-isoelectric focusing combination
US4441978A (en) * 1981-06-29 1984-04-10 Ionics Incorporated Separation of proteins using electrodialysis - isoelectric focusing combination
US4533447A (en) * 1983-06-13 1985-08-06 Meldon Jerry H Apparatus for and method of isoelectric focussing
US4711722A (en) * 1983-10-12 1987-12-08 Ajinomoto Co., Inc. Method for preventing fouling of electrodialysis membrane
US4746647A (en) * 1984-05-28 1988-05-24 Stefan Svenson Purifying protein or peptide recombinant DNA products by electroseparation
US4780411A (en) * 1984-09-22 1988-10-25 Bayer Aktiengesellschaft Water-absorbing, essentially water-free membrane for reagent substrates and methods of preparing the same
US4661224A (en) * 1984-11-26 1987-04-28 Ionics, Incorporated Process and apparatus for electrically desorbing components selectively sorbed on an electrolytically conducting barrier
US4608140A (en) * 1985-06-10 1986-08-26 Ionics, Incorporated Electrodialysis apparatus and process
US4673483A (en) * 1986-03-20 1987-06-16 Ionics Incorporated Isoelectric focusing apparatus
US4897169A (en) * 1986-08-18 1990-01-30 Milan Bier Process and apparatus for recycling isoelectric focusing and isotachophoresis
US5082548A (en) * 1987-04-11 1992-01-21 Ciba-Geigy Corporation Isoelectric focusing apparatus
US5043048A (en) * 1987-07-17 1991-08-27 Muralidhara Harapanahalli S Electromembrane apparatus and process for preventing membrane fouling
US5114555A (en) * 1988-01-05 1992-05-19 Monsanto Company Continuous isoelectric separation
US5015388A (en) * 1988-03-25 1991-05-14 Hospal Industrie Integrated device for the biospecific purification of a liquid containing cellular elements
US5087338A (en) * 1988-11-15 1992-02-11 Aligena Ag Process and device for separating electrically charged macromolecular compounds by forced-flow membrane electrophoresis
US4963236A (en) * 1989-03-08 1990-10-16 Ampholife Technologies Apparatus and methods for isoelectric focusing
US5160594A (en) * 1989-03-08 1992-11-03 Board Of Regents Of The University Of Texas System Apparatus and methods for isoelectric focusing of amphoteric substances incorporating ion selective membranes in electrode chambers
US5127999A (en) * 1989-04-06 1992-07-07 Bayer Aktiengesellschaft Process for the preparation of alkali metal dichromates and chromic acid by electrolysis
US5080770A (en) * 1989-09-11 1992-01-14 Culkin Joseph B Apparatus and method for separating particles
US6093296A (en) * 1990-02-28 2000-07-25 Aclara Biosciences, Inc. Method and device for moving molecules by the application of a plurality of electrical fields
US5096547A (en) * 1990-06-23 1992-03-17 Bayer Aktiengesellschaft Preparation of chromic acid using bipolar membranes
US5173164A (en) * 1990-09-11 1992-12-22 Bioseparations, Inc. Multi-modality electrical separator apparatus and method
US5336387A (en) * 1990-09-11 1994-08-09 Bioseparations, Inc. Electrical separator apparatus and method of counterflow gradient focusing
US5352343A (en) * 1990-10-06 1994-10-04 The University Of Bradford Separation of the components of liquid dispersions
US5340449A (en) * 1990-12-07 1994-08-23 Shukla Ashok K Apparatus for electroelution
US5733442A (en) * 1990-12-07 1998-03-31 Shukla; Ashok K. Microdialysis/Microelectrodialysis system
US5277774A (en) * 1991-06-26 1994-01-11 Shmidt Joseph L Free flow electrophoresis method
US5185086A (en) * 1991-07-16 1993-02-09 Steven Kaali Method and system for treatment of blood and/or other body fluids and/or synthetic fluids using combined filter elements and electric field forces
US5441646A (en) * 1991-08-22 1995-08-15 Bayer Aktiengesellschaft Process of removing sulfate ions from water with a poly(meth)acrylamide exchange resin
US5238570A (en) * 1991-10-31 1993-08-24 Bayer Aktiengesellschaft Asymmetric semipermeable membranes of aromatic polycondensates, processes for their preparation and their use
US5420047A (en) * 1992-11-13 1995-05-30 Bayer Aktiengesellschaft Method for carrying out immunodiagnostic tests
US5407553A (en) * 1992-12-08 1995-04-18 Osmotek Inc. Turbulent flow electrodialysis cell
US5504239A (en) * 1993-06-14 1996-04-02 Bayer Aktiengesellschaft Process for separating off alkanols from other organic compounds of higher carbon number
US5503744A (en) * 1993-10-07 1996-04-02 Sanyo Electric Co., Ltd. Biological oscillating device
US5565102A (en) * 1993-11-09 1996-10-15 Bayer Aktiengesellschaft Process for purifying organic synthesis products
US5437774A (en) * 1993-12-30 1995-08-01 Zymogenetics, Inc. High molecular weight electrodialysis
US5490939A (en) * 1994-03-03 1996-02-13 Bayer Aktiengesellschaft Process for reconcentrating overspray from one-component coating compositions
US5558753A (en) * 1994-05-20 1996-09-24 U.S. Filter/Ionpure, Inc. Polarity reversal and double reversal electrodeionization apparatus and method
US5736023A (en) * 1994-05-20 1998-04-07 U.S. Filter/Ionpure, Inc. Polarity reversal and double reversal electrodeionization apparatus and method
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
US5610285A (en) * 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5662813A (en) * 1994-10-21 1997-09-02 Bioseparations, Inc. Method for separation of nucleated fetal erythrocytes from maternal blood samples
US5906724A (en) * 1994-10-21 1999-05-25 Bioseparations, Inc. Apparatus for separation of nucleated blood cells from a blood sample
US5723031A (en) * 1994-10-31 1998-03-03 Bayer Aktiengesellschaft Method for the analytical separation of viruses
US6117297A (en) * 1995-03-23 2000-09-12 Ionics, Incorporated Electrodialysis apparatus
US5868938A (en) * 1995-12-11 1999-02-09 Bayer Aktiengesellschaft Chiral stationary phases for chromatographic separation of optical isomers
US6129842A (en) * 1995-12-15 2000-10-10 Bayer Aktiengesellschaft Multiphase extractor
US5938904A (en) * 1996-03-27 1999-08-17 Curagen Corporation Separation of charged particles by a spatially and temporally varying electric field
US5891736A (en) * 1996-06-21 1999-04-06 Bayer Corporation Reagents and methods for releasing and measuring lead ions from biological matrices
US6171825B1 (en) * 1997-04-18 2001-01-09 Bayer Corporation Preparation of recombinant factor VIII in a protein free medium
US5869275A (en) * 1998-07-20 1999-02-09 Huang; Eric Z. Affinity ultrafiltration assay for transferase activity
US6328869B1 (en) * 1998-09-07 2001-12-11 Gradipore Limited Apparatus for macromolecule purification
US20020023842A1 (en) * 1998-09-07 2002-02-28 David Ogle Apparatus for macromolecule purification
US5986075A (en) * 1999-01-20 1999-11-16 Bayer Corporation Process for the production of diazonium compounds with a low content of sodium ions
US6402913B1 (en) * 1999-04-12 2002-06-11 Gradipore Limited Separation of plasma components
US6284115B1 (en) * 1999-09-21 2001-09-04 Agilent Technologies, Inc. In-line flow through micro-dialysis apparatus and method for high performance liquid phase separations
US20010052462A1 (en) * 2000-04-18 2001-12-20 David Ogle Small separation apparatus
US20030213748A1 (en) * 2000-09-14 2003-11-20 Juzer Jangbarwala Electrophoretic cross-flow membrane filter system

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080067070A1 (en) * 2003-05-15 2008-03-20 Dennis Rylatt Cell Separation
US8088265B2 (en) * 2003-05-15 2012-01-03 NuSep Holdings Ltd. Cell separation
US20090101507A1 (en) * 2003-10-07 2009-04-23 Aitken Robert J Sperm cell separation by electrophoresis
US8123924B2 (en) 2003-10-07 2012-02-28 Newcastle Innovation Limited Sperm cell separation by electrophoresis

Also Published As

Publication number Publication date
WO2001078876A1 (en) 2001-10-25
US6660150B2 (en) 2003-12-09
US20020148730A1 (en) 2002-10-17
AUPQ691400A0 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
US6660150B2 (en) Separation of micromolecules
Van de Merbel Membrane-based sample preparation coupled on-line to chromatography or electrophoresis
US5080770A (en) Apparatus and method for separating particles
JP5323933B2 (en) Pump supply switching and desalting of amplified dynamic current bodies
Righetti et al. Preparative purification of human monoclonal antibody isoforms in a multi-compartment electrolyser with immobiline membranes
US7390389B2 (en) Apparatus and method for separating an analyte
US20050167270A1 (en) Electrophoresis apparatus and method
US20030019753A1 (en) Multi-port separation apparatus and method
AU764951B2 (en) Small separation apparatus
Grib et al. Amino acid retention with alumina γ nanofiltration membrane
Levin et al. Continuous separation of proteins in electrical split-flow thin (SPLITT) cell with equilibrium operation
Morales-Cid et al. Sample treatments improved by electric fields
Galier et al. Study of the mass transfer phenomena involved in an electrophoretic membrane contactor
EP1284808A1 (en) Separation of micromolecules
AU5016001A (en) Separation of micromolecules
US6800184B2 (en) Electrophoresis separation and treatment of samples
Hayakawa et al. Evaluation of the electroosmotic medium pump system for preparative disk gel electrophoresis
US20030006142A1 (en) Radial electrophoresis apparatus and method
EP1664756A1 (en) Electrophoresis membrane support and manifold unit
US20020170831A1 (en) Apparatus and method for separation of molecules and movement of fluids
JPS59171850A (en) Separation of protein
AU2002256552B2 (en) Apparatus and method for separation of molecules and movement of fluids
Lee Membrane separation coupled with electrophoresis
AU2001291491B2 (en) Electrophoresis apparatus and method
Poggel et al. Transport phenomena in free flow zone electrophoresis

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION